Product
ATGC-110
1 clinical trial
1 indication
Indication
Glabellar Frown LinesClinical trial
A Randomized, Double-Blind, Active-Control, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of "ATGC-110" Compared to "Xeomin®" in Patients Who Need Moderate or Severe Glabellar Line ImprovementStatus: Active (not recruiting), Estimated PCD: 2023-02-10